S&P 500   4,172.98 (-0.77%)
DOW   32,815.86 (-0.69%)
QQQ   346.98 (-0.86%)
AAPL   178.59 (+0.73%)
MSFT   328.60 (-0.79%)
META   261.47 (-0.40%)
GOOGL   123.00 (-0.54%)
AMZN   119.35 (-1.90%)
TSLA   196.67 (-2.23%)
NVDA   382.54 (-4.63%)
NIO   7.35 (-0.81%)
BABA   78.65 (-0.03%)
AMD   118.74 (-5.21%)
T   15.82 (+1.15%)
F   12.03 (-4.45%)
MU   68.43 (-4.55%)
CGC   0.81 (-5.33%)
GE   100.52 (-1.84%)
DIS   87.54 (-0.32%)
AMC   4.38 (-5.40%)
PFE   37.56 (+1.49%)
PYPL   61.44 (-0.98%)
NFLX   390.96 (-0.51%)
S&P 500   4,172.98 (-0.77%)
DOW   32,815.86 (-0.69%)
QQQ   346.98 (-0.86%)
AAPL   178.59 (+0.73%)
MSFT   328.60 (-0.79%)
META   261.47 (-0.40%)
GOOGL   123.00 (-0.54%)
AMZN   119.35 (-1.90%)
TSLA   196.67 (-2.23%)
NVDA   382.54 (-4.63%)
NIO   7.35 (-0.81%)
BABA   78.65 (-0.03%)
AMD   118.74 (-5.21%)
T   15.82 (+1.15%)
F   12.03 (-4.45%)
MU   68.43 (-4.55%)
CGC   0.81 (-5.33%)
GE   100.52 (-1.84%)
DIS   87.54 (-0.32%)
AMC   4.38 (-5.40%)
PFE   37.56 (+1.49%)
PYPL   61.44 (-0.98%)
NFLX   390.96 (-0.51%)
S&P 500   4,172.98 (-0.77%)
DOW   32,815.86 (-0.69%)
QQQ   346.98 (-0.86%)
AAPL   178.59 (+0.73%)
MSFT   328.60 (-0.79%)
META   261.47 (-0.40%)
GOOGL   123.00 (-0.54%)
AMZN   119.35 (-1.90%)
TSLA   196.67 (-2.23%)
NVDA   382.54 (-4.63%)
NIO   7.35 (-0.81%)
BABA   78.65 (-0.03%)
AMD   118.74 (-5.21%)
T   15.82 (+1.15%)
F   12.03 (-4.45%)
MU   68.43 (-4.55%)
CGC   0.81 (-5.33%)
GE   100.52 (-1.84%)
DIS   87.54 (-0.32%)
AMC   4.38 (-5.40%)
PFE   37.56 (+1.49%)
PYPL   61.44 (-0.98%)
NFLX   390.96 (-0.51%)
S&P 500   4,172.98 (-0.77%)
DOW   32,815.86 (-0.69%)
QQQ   346.98 (-0.86%)
AAPL   178.59 (+0.73%)
MSFT   328.60 (-0.79%)
META   261.47 (-0.40%)
GOOGL   123.00 (-0.54%)
AMZN   119.35 (-1.90%)
TSLA   196.67 (-2.23%)
NVDA   382.54 (-4.63%)
NIO   7.35 (-0.81%)
BABA   78.65 (-0.03%)
AMD   118.74 (-5.21%)
T   15.82 (+1.15%)
F   12.03 (-4.45%)
MU   68.43 (-4.55%)
CGC   0.81 (-5.33%)
GE   100.52 (-1.84%)
DIS   87.54 (-0.32%)
AMC   4.38 (-5.40%)
PFE   37.56 (+1.49%)
PYPL   61.44 (-0.98%)
NFLX   390.96 (-0.51%)
NASDAQ:CRVS

Corvus Pharmaceuticals (CRVS) Stock Forecast, Price & News

$3.07
-0.02 (-0.65%)
(As of 12:44 PM ET)
Compare
Today's Range
$2.97
$3.25
50-Day Range
$0.65
$3.37
52-Week Range
$0.61
$3.70
Volume
368,114 shs
Average Volume
525,221 shs
Market Capitalization
$142.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.83

Corvus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
88.8% Upside
$5.83 Price Target
Short Interest
Healthy
1.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of Corvus Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$24,500 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.47) to ($0.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

247th out of 1,006 stocks

Pharmaceutical Preparations Industry

110th out of 492 stocks


CRVS stock logo

About Corvus Pharmaceuticals (NASDAQ:CRVS) Stock

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.

Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRVS Stock News Headlines

AI Getting Close to Thinking Like Humans
Technology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.
146 Pounds of Graphite Needed for Each EV
Graphite - not lithium - is the largest component of lithium-ion batteries used in electric vehicles. That's why 97 more graphite mines will be needed by 2035 just to keep up with battery demand for the $7 trillion EV market.
See More Headlines
Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRVS Company Calendar

Last Earnings
3/28/2023
Today
5/31/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRVS
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.83
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$3.50
Forecasted Upside/Downside
+2.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-41,310,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.21 per share

Miscellaneous

Free Float
32,738,000
Market Cap
$143.90 million
Optionable
Not Optionable
Beta
1.17

Key Executives

  • Richard A. MillerRichard A. Miller
    Chairman, President & Chief Executive Officer
  • Leiv Lea
    Chief Financial Officer
  • Gabriel Luciano
    Vice President-Clinical Operations
  • Suresh Mahabhashyam
    Vice President-Clinical Development
  • James Rosenbaum
    Senior Vice President-Research













CRVS Stock - Frequently Asked Questions

Should I buy or sell Corvus Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRVS shares.
View CRVS analyst ratings
or view top-rated stocks.

What is Corvus Pharmaceuticals' stock price forecast for 2023?

3 Wall Street analysts have issued 1 year price targets for Corvus Pharmaceuticals' shares. Their CRVS share price forecasts range from $3.50 to $10.00. On average, they expect the company's stock price to reach $5.83 in the next year. This suggests a possible upside of 88.8% from the stock's current price.
View analysts price targets for CRVS
or view top-rated stocks among Wall Street analysts.

How have CRVS shares performed in 2023?

Corvus Pharmaceuticals' stock was trading at $0.85 at the beginning of the year. Since then, CRVS stock has increased by 263.5% and is now trading at $3.09.
View the best growth stocks for 2023 here
.

Are investors shorting Corvus Pharmaceuticals?

Corvus Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 455,500 shares, an increase of 209.2% from the April 30th total of 147,300 shares. Based on an average trading volume of 713,100 shares, the days-to-cover ratio is currently 0.6 days. Approximately 1.3% of the company's shares are sold short.
View Corvus Pharmaceuticals' Short Interest
.

When is Corvus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CRVS earnings forecast
.

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) announced its quarterly earnings data on Tuesday, March, 28th. The company reported ($0.21) EPS for the quarter.

What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO?

4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend.

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include CHI Advisors LLC (5.02%), Renaissance Technologies LLC (1.09%), Two Sigma Investments LP (0.44%), Two Sigma Advisers LP (0.40%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Ecor1 Capital, Llc, Holdings A/S Novo, Leiv Lea, Linda Grais, Orbimed Advisors Llc, Richard A Md Miller and William Benton Jones.
View institutional ownership trends
.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corvus Pharmaceuticals' stock price today?

One share of CRVS stock can currently be purchased for approximately $3.09.

How much money does Corvus Pharmaceuticals make?

Corvus Pharmaceuticals (NASDAQ:CRVS) has a market capitalization of $143.90 million. The company earns $-41,310,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The official website for the company is www.corvuspharma.com. The company can be reached via phone at (650) 900-4520 or via email at llea@corvuspharma.com.

This page (NASDAQ:CRVS) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -